AbbVie (ABBV) Tops Q2 EPS by 3c, Maintains FY EPS Guidance

AbbVie (NYSE: ABBV) reported Q2 EPS of $3.37, $0.03 better than the analyst estimate of $3.34. Revenue for the quarter came in at $14.58 billion versus the consensus estimate of $14.67 billion.

GUIDANCE:

AbbVie sees FY2022 EPS of $13.78-$13.98, versus the consensus of $13.91.

• AbbVie is confirming its adjusted diluted EPS guidance range for the full-year 2022 of $13.78 - $13.98 which includes an unfavorable impact of $0.23 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2022. The company's 2022 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2022, as both cannot be reliably forecasted.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection